Lv5
870 积分 2022-02-15 加入
Su1326 DEVELOPING TEV-53408 FOR THE TREATMENT OF CELIAC DISEASE: SUMMARY OF PRELIMINARY RESULTS FROM THE FIRST IN HUMAN PHASE 1 STUDY IN HEALTHY VOLUNTEERS
12天前
已完结
Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study
17天前
已完结
Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study
17天前
已完结
Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study
18天前
已完结
AZD5305 More Tolerable than Earlier PARP Agents
1个月前
已完结
Handbook of Pharmaceutical Excipients – 7th Edition
1个月前
已完结
A good practice guide to the administration of substances and removal of blood, including routes and volumes
1个月前
已完结
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
2个月前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
2个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
2个月前
已完结
皖公网安备34019202002308
